https://www.selleckchem.com/pr....oducts/plumbagin.htm
74. The 6-month OS rates in low and high NLR groups were 75.5% and 18.8% (P  less then  0.001). In the univariate analysis, advanced age (P = 0.003), metastatic pancreatic cancer (P = 0.037), no treatment (P  less then  0.001), worse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) (P  less then  0.001), high GPS (P  less then  0.001), high modified GPS (P  less then  0.001), high NLR (P  less then  0.001), high PLR (P = 0.002), high CRP/Alb ratio (P  less then  0.001), and low PNI (P  less then  0.001) were identified